Why IMU is a multi multi bagger, page-13451

Bell Potter quoted the following in their lates report:

"The major short term catalyst is the readout from the phase 1 MAST
study investigating CF33 in the treatment of solid tumors both as monotherapy and in
various combinations with pembrolizumab."

Bell Potter have obviously had in depth discussions with management and this IMO is the most important piece of information in their report. We've had many, many clues as to what's happening in the MAST trial and a readout would only be happening to communicate great results. I expect it prior to Yuman visiting in late July.

I'm hoping for and expecting official confirmation of everything we've been hearing. Published results, complete responses, zero toxicity etc.

I also wouldn't be surprised if we see a deal announced anytime from now, either licensing or takeover.

If CF33 works in humans as well as in mice then we are on the cusp of something I can't actually fathom. Exciting times and the share price is an absolute bargain IMO. So much in play right now.

GLTAH. DYOR!